$0.51 +0.05 (%) OncoGenex Pharmaceuticals Inc - NASDAQ

Dec. 9, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

    Benzinga | Jan. 20, 2016 | 16:02PM EST
  2. OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial

    Benzinga | Dec. 9, 2015 | 07:01AM EST
  3. Benzinga's Top Downgrades

    Benzinga | Dec. 2, 2015 | 09:31AM EST
  4. OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

    Benzinga | Oct. 8, 2015 | 06:00AM EST
  5. OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

    Benzinga | Sep. 30, 2015 | 06:03AM EST
  6. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 28, 2015 | 07:14AM EST
  7. OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

    Benzinga | Sep. 28, 2015 | 03:05AM EST
  8. US Stock Futures Rise Ahead Of Manufacturing PMI

    Benzinga | Sep. 23, 2015 | 06:52AM EST
  9. OncoGenex Pharma Offers Phase 2 Rainier Results Related to Previously Untreated Metastatic Pancreatic Cancer

    Benzinga | Sep. 23, 2015 | 06:02AM EST
  10. An Update On Phase 3 ENSPIRIT Trial - Report on OncoGenex Pharmaceuticals

    Benzinga | Aug. 4, 2015 | 08:22AM EST
  11. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Jul. 13, 2015 | 06:16AM EST
  12. OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis

    Benzinga | Jul. 13, 2015 | 06:01AM EST
  13. FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

    Benzinga | Jun. 10, 2015 | 06:00AM EST
  14. US Stock Futures Slip Ahead Of Home Price, Consumer Confidence Data

    Benzinga | Dec. 30, 2014 | 07:10AM EST
  15. OncoGenex to Regain Rights to Custirsen from Teva

    Benzinga | Dec. 30, 2014 | 07:03AM EST
  16. US Stock Futures Edge Lower; Crude Oil Drops

    Benzinga | Dec. 16, 2014 | 07:03AM EST
  17. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  18. George Soros Had A Mixed Day On The Market

    GuruFocus | Oct. 30, 2014 | 10:21AM EST
  19. OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

    Benzinga | Aug. 21, 2014 | 15:02PM EST
  20. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 29, 2014 | 09:26AM EST
  21. Morning Market Losers

    Benzinga | Apr. 28, 2014 | 08:51AM EST
  22. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 28, 2014 | 07:09AM EST
  23. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with First-Line Docetaxel, Prednisone, Primary End Point Was Not Reached

    Benzinga | Apr. 28, 2014 | 06:21AM EST
  24. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga | Feb. 27, 2014 | 11:06AM EST
  25. US Stock Futures Down Ahead Of Home Prices, Consumer Confidence Data

    Benzinga | Aug. 27, 2013 | 06:20AM EST
  26. OncoGenex Inititiates Rainier Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE plus Gemcitabine

    Benzinga | Aug. 27, 2013 | 05:34AM EST
  27. OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in Combo with Zytiga

    Benzinga | Dec. 19, 2012 | 02:33AM EST
  28. ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 11:36AM EST
  29. OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer

    Benzinga | Sep. 27, 2012 | 09:30AM EST
  30. ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q)

    GuruFocus | Aug. 2, 2012 | 12:29PM EST
  31. Health Care Sector Wrap

    FoxBusiness | Jul. 19, 2012 | 09:52AM EST
  32. UPDATE: Bloom Burton Maintains Buy Rating, Lowers PT for OncoGenex

    Benzinga | May. 4, 2012 | 04:08AM EST
  33. UPDATE: Stifel NIcolaus Cuts Target on OncoGenex Pharmaceuticals to $35

    Benzinga | Mar. 9, 2012 | 06:15AM EST
  34. UPDATE: Bloom Burton Cuts PT to $24 on OncoGenex Pharmaceuticals

    Benzinga | Mar. 9, 2012 | 05:24AM EST
Trading Center